Healthcare provider profile · identity verified

Henry Peng, MD

Family Practice · ARCADIA, CA · NPI 1144378167

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	396	121
Levothyroxine Sodium	Levothyroxine Sodium	321	86
Rosuvastatin Calcium	Rosuvastatin Calcium	307	103
Amlodipine Besylate	Amlodipine Besylate	227	71
Metformin Hcl	Metformin Hcl	192	57
Losartan Potassium	Losartan Potassium	163	46
Lisinopril	Lisinopril	153	45
Escitalopram Oxalate	Escitalopram Oxalate	136	45
Metoprolol Succinate	Metoprolol Succinate	126	35
Omeprazole	Omeprazole	109	31
Alprazolam	Alprazolam	103	40
Trazodone Hcl	Trazodone Hcl	95	27
Gabapentin	Gabapentin	94	35
Methylprednisolone	Methylprednisolone	94	77
Tramadol Hcl	Tramadol Hcl	92	53
Simvastatin	Simvastatin	89	23
Azithromycin	Azithromycin	86	74
Tamsulosin Hcl	Tamsulosin Hcl	86	27
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	83	32
Bupropion Xl	Bupropion Hcl	80	16
Albuterol Sulfate Hfa	Albuterol Sulfate	75	20
Allopurinol	Allopurinol	74	22
Alendronate Sodium	Alendronate Sodium	73	24
Furosemide	Furosemide	69	22
Pantoprazole Sodium	Pantoprazole Sodium	64	20
Memantine Hcl	Memantine Hcl	63	14
Carvedilol	Carvedilol	58	23
Jardiance	Empagliflozin	49	16
Montelukast Sodium	Montelukast Sodium	49	16
Hydrochlorothiazide	Hydrochlorothiazide	48	18
Finasteride	Finasteride	44	14
Synthroid	Levothyroxine Sodium	44	15
Zolpidem Tartrate	Zolpidem Tartrate	44	11
Lovastatin	Lovastatin	41	11
Prednisone	Prednisone	41	26
Diclofenac Sodium	Diclofenac Sodium	40	13
Quetiapine Fumarate	Quetiapine Fumarate	39	12
Eliquis	Apixaban	38	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	37	12
Cephalexin	Cephalexin	36	32
Donepezil Hcl	Donepezil Hcl	35	11
Temazepam	Temazepam	35	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	35	suppressed
Meclizine Hcl	Meclizine Hcl	34	12
Mirtazapine	Mirtazapine	34	suppressed
Sertraline Hcl	Sertraline Hcl	34	15
Meloxicam	Meloxicam	33	16
Potassium Chloride	Potassium Chloride	33	11
Citalopram Hbr	Citalopram Hydrobromide	32	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	32	30
Pregabalin	Pregabalin	32	suppressed
Atenolol	Atenolol	29	11
Clopidogrel	Clopidogrel Bisulfate	29	12
Estradiol	Estradiol	29	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	29	13
Benazepril Hcl	Benazepril Hcl	28	suppressed
Lorazepam	Lorazepam	28	12
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	28	19
Olmesartan Medoxomil	Olmesartan Medoxomil	28	suppressed
Valsartan	Valsartan	28	suppressed
Glipizide	Glipizide	27	suppressed
Metformin Hcl Er	Metformin Hcl	27	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	26	22
Famotidine	Famotidine	26	12
Irbesartan	Irbesartan	26	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	26	19
Pravastatin Sodium	Pravastatin Sodium	25	suppressed
Fluticasone Propionate	Fluticasone Propionate	24	11
Ibuprofen	Ibuprofen	23	suppressed
Naproxen	Naproxen	23	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	23	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	suppressed
Spironolactone	Spironolactone	21	suppressed
Eszopiclone	Eszopiclone	20	suppressed
Ezetimibe	Ezetimibe	20	suppressed
Methocarbamol	Methocarbamol	20	14
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	17
Ondansetron Hcl	Ondansetron Hcl	19	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Ozempic	Semaglutide	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	12
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	16	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	suppressed
Baclofen	Baclofen	15	suppressed
Diazepam	Diazepam	15	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	15	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Multaq	Dronedarone Hcl	13	suppressed
Nebivolol Hcl	Nebivolol Hcl	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Rybelsus	Semaglutide	13	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Glimepiride	Glimepiride	12	suppressed
Ketoconazole	Ketoconazole	12	11
Metoprolol Tartrate	Metoprolol Tartrate	12	suppressed
Prolia	Denosumab	12	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Methimazole	Methimazole	11	suppressed
Primidone	Primidone	11	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error